ReviewEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2019
New antimicrobial options for the management of complicated intra-abdominal infections.
Review in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05549076 (Complicated Intra-abdominal Infections - the Greek Reality), which is not on this map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Complicated Intra-abdominal Infections - the Greek Reality: a Prospective Observational Study
Who cites it
21 citing papers in PubMed, 41 citations in OpenAlex.
- Temocillin: A Narrative Review of Its Clinical Reappraisal.Antibiotics (Basel, Switzerland) · 2025Review
- Editorial: Advances in intra-abdominal infection.Frontiers in medicine · 2025Article
- The challenge of antimicrobial resistance (AMR): current status and future prospects.Naunyn-Schmiedeberg's archives of pharmacology · 2024Review
- Author Response: Unanswered Questions and Contradictory Statements in the Antibiotics Prescription Guidelines.Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine · 2024Article
- A descriptive pharmacokinetic/pharmacodynamic analysis of ceftazidime-avibactam in a case series of critically ill patients with augmented renal clearance.Pharmacology research & perspectives · 2024Article
- Antimicrobial approach of abdominal post-surgical infections.World journal of gastrointestinal surgery · 2023Review
- Antibiotic treatment in cirrhotic patients.World journal of clinical cases · 2023Article
- Molecular docking-based virtual screening, drug-likeness, and pharmacokinetic profiling of some anti-Journal of Taibah University Medical Sciences · 2023Article
- "Emerging Topics in Pain Medicine": Advancing Research and Patient-Centered Health Strategies.Journal of personalized medicine · 2023Article
- Antibiotic Therapy Strategies for Treating Gram-Negative Severe Infections in the Critically Ill: A Narrative Review.Antibiotics (Basel, Switzerland) · 2023Review
- Burden of severe infections due to carbapenem-resistant pathogens in intensive care unit.World journal of clinical cases · 2023Review
- The Need of Antimicrobial Stewardship in Post-Operative Infectious Complications of Abdominal Surgery.Visceral medicine · 2022Review
- Early Diagnosis and Antibiotic Treatment Combined with Multicomponent Hemodynamic Support for Addressing a Severe Case of Lemierre's Syndrome.Antibiotics (Basel, Switzerland) · 2021Article
- Clinical Pharmacokinetics and Pharmacodynamics of Lefamulin.Clinical pharmacokinetics · 2021Review
- Advances in novel antibiotics to treat multidrug-resistant gram-negative bacterial infections.Internal and emergency medicine · 2021Review
- Composite Inflammatory Indicators as Early Predictor of Intra-abdominal Infections after General Surgery.Journal of inflammation research · 2021Article
- Spontaneous bacterial peritonitis due to carbapenemase-producingWorld journal of hepatology · 2020Review
- Pharmacokinetics of imipenem in both plasma and peritoneal draining liquid in elder patients with perforated upper gastrointestinal tract.European journal of clinical pharmacology · 2020Article
- Trends, Epidemiology, and Management of Multi-Drug Resistant Gram-Negative Bacterial Infections in the Hospitalized Setting.Antibiotics (Basel, Switzerland) · 2020Review
- Resistance of Gram-Negative Bacteria to Current Antibacterial Agents and Approaches to Resolve It.Molecules (Basel, Switzerland) · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Complicated intra-abdominal infections (cIAIs) are a common cause of morbidity and mortality in surgical patients. Optimal management of cIAI requires early source control in combination with adequate antimicrobial treatment and aggressive fluid resuscitation. cIAIs are mainly caused by Gram-negative bacilli and anaerobes. Broad-spectrum single-agent or combination drug regimens against these microorganisms are the mainstay of therapy. However, development of antimicrobial resistance has become an increasingly large concern: multidrug-resistant organisms are associated with a higher rate of inadequate antimicrobial therapy, which in turn is associated with higher mortality rate, longer hospital stay, and increased cost compared to adequate antimicrobial therapy. In this mini-review, we discuss the effectiveness of several new antimicrobial agents, recently approved or in advanced phases of clinical development, for the treatment of cIAIs, including the new beta-lactam and beta-lactamase inhibitor combinations (ceftolozane/tazobactam, ceftazidime/avibactam, meropenem/vaborbactam, imipenem/cilastatin/relebactam, aztreonam/avibactam), siderophore cephalosporins (cefiderocol), aminoglycosides (plazomicin), and tetracyclines (eravacycline).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.